menu
    • menu
    [{"orgOrder":0,"company":"AI Proteins","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Miniprotein-Based Therapeutics","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AI Proteins","amount2":0.40000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"AI Proteins \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"AI Proteins \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AI Proteins","sponsor":"University of Missouri-Columbia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AI Proteins","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AI Proteins \/ University of Missouri-Columbia","highestDevelopmentStatusID":"4","companyTruncated":"AI Proteins \/ University of Missouri-Columbia"}]

    Find Clinical Drug Pipeline Developments & Deals by AI Proteins

    Menu

    AI Proteins

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AI Proteins

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            AI Proteins

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : University of Missouri-Columbia

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AI Proteins Signs Collaborative Research Agreement on Radioligand Therapy

                            Details : The collaboration aims to advance the use of de novo designed miniproteins for targeted radioligand therapy, labeled with alpha and beta-emitting radionuclides are effective as a cancer theranostic.

                            Product Name : Undisclosed

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Undisclosed

                            January 08, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : University of Missouri-Columbia

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AI Proteins

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            AI Proteins

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Miniprotein-Based Therapeutics

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $400.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bristol Myers Squibb Taps AI Proteins in Drug Discovery Collaboration Worth Up to $400M

                            Details : Under the collaboration, AI Proteins will leverage its proprietary AI-driven platform to design and optimize novel miniprotein-based therapeutics against targets of interest to Bristol Myers Squibb.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 03, 2024

                            Lead Product(s) : Miniprotein-Based Therapeutics

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $400.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth